Table 1.
Table describing clinico-pathologic and genetic characteristics of chronic myelomonocytic leukemia treated with allogeneic hematopoietic stem cell transplant.
| Variables | All CMML patients who underwent HCT (n = 70) | CMML patients who underwent HCT in chronic phase (n = 46) | CMML patients who underwent HCT after blast transformation (n = 24) | P-value |
|---|---|---|---|---|
| Age in years; median (range) | 58 (18–73) | 58 (26–72) | 57 (18–73) | 0.24 |
| Sex (Male); n (%) | 45 (64) | 31 (67) | 14 (58) | 0.45 |
| Hemoglobin g/dL; median (range) | 9.5 (6.4–12.5) | 9.1 (6.4–12.5) | 10 (6.7–12.2) | 0.02 |
| WBC × 109/L; median (range) | 1.6 (0.1–52.1) | 1.8 (0.1–52.1) | 1.1 (0.1–6) | 0.10 |
| ANC × 109/L; median (range) | 1.5 (0–43.2) | 1.4 (0–43.2) | 1.7 (0–5.6) | 0.83 |
| Platelets × 109/L; median (range) | 56 (7–277) | 47 (7–194) | 65 (18–277) | 0.07 |
| Palpable splenomegaly at transplant; n (%) | 9 (13) | 5 (11) | 4 (18) | 0.43 |
| Prior therapies; n (%) | N = 68 | N = 44 | N = 24 | <0.0001 |
| Observation/supportive care | 10 (15) | 10 (23) | 0 (0) | |
| HMA | 22 (32) | 21 (48) | 1 (4) | |
| AML-like induction chemotherapy | 18 (27) | 5 (11) | 13 (54) | |
| HMA followed by induction chemotherapy | 12 (18) | 2 (4) | 10 (42) | |
| Clinical trial | 3 (4) | 3 (7) | 0 (0) | |
| Other | 3 (4) | 3 (7) | 0 (0) | |
| Disease status at transplant; n (%) | N = 67 | N = 44 | N = 23 | 0.0004 |
| Complete remission | 23 (34) | 8 (18) | 15 (65) | |
| Marrow response | 22 (33) | 17 (39) | 5 (22) | |
| Stable disease | 8 (12) | 8 (18) | 0 (0) | |
| Disease progression | 14 (21) | 11 (25) | 3 (13) | |
| Time to transplant from diagnosis in months; median (range) | 5 (0–44) | 7 (0–22) | 7 (2–44) | 0.33 |
| HCT-CI; n (%) | N = 68 | N = 45 | N = 23 | 0.30 |
| Group 1 (0) | 16 (24) | 8 (18) | 8 (35) | |
| Group 2 (1–2) | 18 (26) | 13 (29) | 5 (22) | |
| Group 3 (≥3) | 34 (50) | 24 (53) | 10 (43) | |
| Type of transplant conditioning; n (%) | N = 68 | N = 46 | N = 22 | 0.61 |
| Myeloablative | 31 (46) | 20 (43) | 11 (50) | |
| Reduced intensity | 37 (54) | 26 (57) | 11 (50) | |
| Donor source; n (%) | N = 67 | N = 45 | N = 22 | 0.83 |
| Matched related donor | 28 (42) | 17 (38) | 11 (50) | |
| Mismatched related donor | 1 (2) | 1 (2) | 0 (0) | |
| Matched unrelated donor | 30 (45) | 22 (49) | 8 (36) | |
| Mismatched unrelated donor | 3 (4) | 2 (4) | 1 (5) | |
| Umbilical cord blood | 2 (3) | 1 (2) | 1 (5) | |
| Haploidentical donor | 3 (4) | 2 (4) | 1 (5) | |
| Graft source; n (%) | N = 68 | N = 45 | N = 23 | 0.76 |
| Peripheral blood | 58 (85) | 38 (85) | 20 (87) | |
| Bone marrow | 8 (12) | 6 (13) | 2 (9) | |
| Umbilical cord | 2 (3) | 1 (2) | 1 (4) | |
| Acute GVHD grade 2–4; n (%) | 29/63 (46) | 17/43 (40) | 12/20 (60) | 0.12 |
| Chronic GVHD; n (%) | N = 41 | N = 30 | N = 11 | 0.24 |
| Mild | 15 (37) | 13 (43) | 2 (18) | |
| Moderate | 14 (34) | 10 (33) | 4 (36) | |
| Severe | 12 (29) | 7 (23) | 5 (45) | |
| GVHD-free, relapse-free survival in months; median (95% CI) | 6 (5–8) | 7 (5–21) | 3.5 (2–7) | 0.02 |
| GRFS at 100 days post HCT in percentage | 70 | 76 | 54 | |
| Posttransplant disease relapse; n (%) | 18 (27) | 11 (24) | 7 (33) | 0.45 |
| Overall survival post transplant; median (95% CI) | 25 (18–189) | 67 (20–189) | 16 (7–39) | 0.06 |
| Deaths | 39 (56) | 22 (48) | 17 (71) | 0.06 |